The NIH pulse cyclophosphamide regime: the end of an era?

Austin HA III , Klippel JH , Balow JE et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs . N Engl J Med 1986; 314: 614-619 .

Martin-Suarez I , D’Cruz D , Mansoor M , Fernandes AP , Khamashta MA , Hughes GRV. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenouscyclophosphamide . Ann Rheum Dis 1997; 56: 481-487 .

D’Cruz D , Cuadrado MJ , Mujic F et al. Immunosuppressive therapy in lupus nephritis . Clin Exp Rheumatol 1997; 15: 275-282 .

Houssiau FA , Vasconcelos C , D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. A randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum 2002; 46: 2121-2131 .

Dooley MA , Hogan S , Jennette C , Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network . Kidney Int 1997; 51: 1188-1195 .

Illei GG , Takada K , Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies . Arthritis Rheum 2002; 46: 995-1002 .

Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation . QJM 2000; 93: 15-20 .

Corna D , Morigi M , Facchinetti D , Bertani T , Zoja C , Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease . Kidney Int 1997; 51: 1583-1589 .

Allison AC , Eugui EM. Mycophenolate mofetil and its mechanisms of action . Immunopharmacology 2000; 47: 85-118 .

Adu D , Cross J , Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil . Lupus 2001; 10: 203-208 .

Moder KG. Mycophenolate mofetil: new applications for this immunosuppressant . Ann Allergy Asthma Immunol 2003; 90: 15-19 .

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . N Engl J Med 2000; 343: 1156-1162 .

Ginzler EM , Aranow C , Buyon J et al. A mulicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results . Arthritis Rheum 2003; 48: S647-S647 .

Contreras G , Pardo V , Leclercq B et al. Lupus nephritis: sequential therapy with short-term intravenous cyclophosphamide followed by maintenance oral mycophenolate mofetil or oral azathioprine is more efficacious and safer than long-term intravenous cyclophosphamide . American Society of Nephrology Annual Meeting 2003.

Karim MY , Alba P , Cuadrado MJ , Abbs IC , D’Cruz DP , Khamashta MA , Hughes GR. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents . Rheumatology (Oxford) 2002; 41: 876-882 .

Cellcept (mycophenolate mofetil). Complete product information. Roche Laboratories Inc. Revised December 2000.